{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Purpose: The study aimed to assess pharmacokinetics and safety of two oxycodone/naloxone prolonged-release tablet formulations in the Chinese population."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomized, open-label, two-period crossover clinical trial."
      },
      "Participants": {
        "score": 2,
        "evidence": "The study was conducted in 36 Chinese patients with chronic pain in both fasting and fed states."
      },
      "Intervention": {
        "score": 2,
        "evidence": "two oxycodone/naloxone prolonged-release tablet formulations"
      },
      "Objective": {
        "score": 1,
        "evidence": "The study aimed to assess pharmacokinetics and safety of two oxycodone/naloxone prolonged-release tablet formulations in the Chinese population."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "No serious adverse events were reported."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The study was conducted in 36 Chinese patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "the mean (\u00b1 standard deviation, SD) peak concentration (C max ), area under concentration\u2013time curve from time 0 to the last measurable concentration (AUC 0\u2013t ) and to infinite time (AUC 0\u2013\u221e ), and elimination half-life (t 1/2 ) of oxycodone for the brand-name and generic formulations were 50.9 \u00b1 10.9 and 52.1 \u00b1 9.58 ng/mL, 577 \u00b1 148 and 554 \u00b1 104 h*ng/mL, 579 \u00b1 150 and 556 \u00b1 104 h*ng/mL, and 5.17 \u00b1 0.834 and 5.10 \u00b1 0.877 h, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "No serious adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}